Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMACPQO)

• Drug Name: Dihydrexidine Drug Info
• Synonyms: DIHYDREXIDINE; (+)-Dihydrexidine; UNII-Q3PJ4B4D0X; Q3PJ4B4D0X; CHEMBL25856; Dihydrexidine hydrochloride; (6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol; (6aR,12bS)-5,6,6a,7,8,12b-Hexahydrobenzo(a)phenanthridine-10,11-diol; Rel-Dihydrexidine; Dihydrexidine, (+)-; Lopac-D-5814; Biomol-NT_000033; AC1O7G2G; Lopac0_000380; 5,6,6a,7,8,12b-Hexahydro-benzo[a]phenanthridine-10,11-diol; BPBio1_001227; SCHEMBL4614575; CHEBI:124993; DAR-0100; IP-202; BDBM50010686; ZINC25758512; CCG-204474; NCGC00024845-04

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 5311070
  CAS Number: CAS 123039-93-0
  TTD Drug ID: DMACPQO

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[6]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[7]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[8]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[9]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[10]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[11]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[12]
CY-208243	DMP8TKA	Pain	MG30-MG3Z	Discontinued in Phase 2	[13]

Drug(s) Affected By Catechol O-methyltransferase (COMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[3]
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[3]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[3]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[14]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[3]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[15]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catechol O-methyltransferase (COMT)	OTPWKTQG	COMT_HUMAN	Biotransformations	[3]

References

• [1] Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015 Jan;40(2):446-53.
• [2] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [3] Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol. 2001 Feb;59(2):393-402. doi: 10.1124/mol.59.2.393.
• [4] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [7] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [8] Clinical pipeline report, company report or official report of Lundbeck.
• [9] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [10] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [11] Clinical pipeline report, company report or official report of Lundbeck
• [12] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [13] The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
• [14] Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep. 2010 Aug;33(8):1027-35. doi: 10.1093/sleep/33.8.1027.
• [15] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [16] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [17] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [18] Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord. 2001 Apr;7(2):93-96. doi: 10.1016/s1353-8020(00)00027-4.
• [19] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.